Colgate-Palmolive (NYSE:CL) PT Raised to $92.00 at Wells Fargo & Company

Colgate-Palmolive (NYSE:CL) had its target price raised by equities research analysts at Wells Fargo & Company from $90.00 to $92.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 0.11% from the stock’s previous close.

A number of other research analysts also recently weighed in on the stock. Citigroup raised their target price on shares of Colgate-Palmolive from $95.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 16th. Morgan Stanley raised their price objective on Colgate-Palmolive from $85.00 to $93.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. Royal Bank of Canada upped their price target on shares of Colgate-Palmolive from $88.00 to $95.00 and gave the stock a “sector perform” rating in a report on Monday. The Goldman Sachs Group initiated coverage on Colgate-Palmolive in a report on Friday, March 1st. They set a “buy” rating and a $93.00 price target for the company. Finally, Evercore ISI upped their price objective on shares of Colgate-Palmolive from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Monday, April 8th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Colgate-Palmolive currently has an average rating of “Moderate Buy” and an average price target of $91.44.

Colgate-Palmolive Trading Up 1.6 %

NYSE CL opened at $91.90 on Monday. The company has a market capitalization of $75.54 billion, a PE ratio of 29.08, a P/E/G ratio of 3.42 and a beta of 0.42. Colgate-Palmolive has a 12 month low of $67.62 and a 12 month high of $92.25. The stock has a 50-day simple moving average of $87.95 and a 200 day simple moving average of $81.92. The company has a current ratio of 0.42, a quick ratio of 0.28 and a debt-to-equity ratio of 8.59.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, April 26th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.04. Colgate-Palmolive had a net margin of 13.22% and a return on equity of 485.40%. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.96 billion. During the same period last year, the firm posted $0.73 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. Research analysts forecast that Colgate-Palmolive will post 3.5 EPS for the current year.

Insider Transactions at Colgate-Palmolive

In other Colgate-Palmolive news, insider Jennifer Daniels sold 3,538 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $84.67, for a total transaction of $299,562.46. Following the completion of the transaction, the insider now directly owns 59,698 shares of the company’s stock, valued at $5,054,629.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Colgate-Palmolive news, EVP Gregory Malcolm sold 8,930 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $85.35, for a total value of $762,175.50. Following the completion of the transaction, the executive vice president now directly owns 8,043 shares of the company’s stock, valued at approximately $686,470.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jennifer Daniels sold 3,538 shares of Colgate-Palmolive stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $84.67, for a total value of $299,562.46. Following the sale, the insider now directly owns 59,698 shares of the company’s stock, valued at approximately $5,054,629.66. The disclosure for this sale can be found here. Insiders sold a total of 229,611 shares of company stock valued at $19,271,879 over the last ninety days. 0.37% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Colgate-Palmolive

Institutional investors have recently made changes to their positions in the stock. Norges Bank bought a new position in Colgate-Palmolive during the fourth quarter valued at approximately $731,843,000. Price T Rowe Associates Inc. MD boosted its stake in Colgate-Palmolive by 16.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 32,133,218 shares of the company’s stock worth $2,561,340,000 after acquiring an additional 4,625,472 shares in the last quarter. Magellan Asset Management Ltd grew its stake in shares of Colgate-Palmolive by 4,162.6% in the 4th quarter. Magellan Asset Management Ltd now owns 2,016,290 shares of the company’s stock worth $160,718,000 after buying an additional 1,968,988 shares during the last quarter. Confluence Investment Management LLC purchased a new stake in shares of Colgate-Palmolive in the first quarter worth $130,622,000. Finally, FMR LLC increased its stake in Colgate-Palmolive by 27.3% during the 3rd quarter. FMR LLC now owns 5,597,742 shares of the company’s stock valued at $398,055,000 after purchasing an additional 1,199,660 shares in the last quarter. Institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.